1,953
Views
69
CrossRef citations to date
0
Altmetric
Reports

MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway

, , , , , , , , , , & show all
Pages 1046-1058 | Received 05 Dec 2014, Accepted 07 Jan 2015, Published online: 01 Apr 2015

References

  • Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64:104-17; PMID:24639052; http://dx.doi.org/10.3322/caac.21220
  • Chen DL, Wang ZQ, Zeng ZL, Wu WJ, Zhang DS, Luo HY, Wang F, Qiu MZ, Wang DS, Ren C, et al. Identification of MicroRNA-214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression. Hepatology 2014; 60:598-609; PMID:24616020; http://dx.doi.org/10.1002/hep.27118
  • Valeri N, Braconi C, Gasparini P, Murgia C, Lampis A, Paulus-Hock V, Hart JR, Ueno L, Grivennikov SI, Lovat F, et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014; 25:469-83; PMID:24735923; http://dx.doi.org/10.1016/j.ccr.2014.03.006
  • Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314:268-74; PMID:16959974; http://dx.doi.org/10.1126/science.1133427
  • De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12:594-603; PMID:21163703; http://dx.doi.org/10.1016/S1470-2045(10)70209-6
  • Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116:281-97; PMID:14744438; http://dx.doi.org/10.1016/S0092-8674(04)00045-5
  • Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009; 11:228-34; PMID:19255566; http://dx.doi.org/10.1038/ncb0309-228
  • Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702
  • Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature Reviews Cancer 2006; 6:857-66; PMID:17060945; http://dx.doi.org/10.1038/nrc1997
  • Li Z, Ying X, Chen H, Ye P, Shen Y, Pan W, Zhang L. MicroRNA-194 Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer Cells by Targeting FoxM1. Dig Dis Sci 2014; 59:2145-52; PMID:24748184; http://dx.doi.org/10.1007/s10620-014-3159-6
  • Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomark Res 2013; 1; PMID:24040515; http://dx.doi.org/10.1186/2050-7771-1-12
  • Khella HW, Bakhet M, Allo G, Jewett MA, Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA, Yousef GM. miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 2013; 34:2231-9; PMID:23715501; http://dx.doi.org/10.1093/carcin/bgt184
  • Wu X, Liu T, Fang O, Leach LJ, Hu X, Luo Z. miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27kip1. Oncogene 2014; 33:1506-14; PMID:23584484; http://dx.doi.org/10.1038/onc.2013.108
  • Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC Jr. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One 2012; 7:e41170; PMID:22829924; http://dx.doi.org/10.1371/journal.pone.0041170
  • Zhang J, Zhao CY, Zhang SH, Yu DH, Chen Y, Liu QH, Shi M, Ni CR, Zhu MH. Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma. Oncol Rep 2014; 31:1157-64; PMID:24398877
  • Chiang Y, Song Y, Wang Z, Liu Z, Gao P, Liang J, Zhu J, Xing C, Xu H. microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer. Exp Ther Med 2012; 3:560-6; PMID:22969930
  • Wang ZH, Ren LL, Zheng P, Zheng HM, Yu YN, Wang JL, Lin YW, Chen YX, Ge ZZ, Chen XY, et al. MiR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. Cancer Prev Res (Phila) 2014; 7:607-16; PMID:24691499; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0426
  • Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, et al. p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res 2011; 71:7490-501; PMID:22028325; http://dx.doi.org/10.1158/0008-5472.CAN-11-1124
  • Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003; 23:2068-82; PMID:12612079; http://dx.doi.org/10.1128/MCB.23.6.2068-2082.2003
  • Rizzardi AE, Rosener NK, Koopmeiners JS, Isaksson VR, Metzger GJ, Forster CL, Marston LO, Tiffany JR, McCarthy JB, Turley EA, et al. Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer 2014; 14:244; PMID:24708576; http://dx.doi.org/10.1186/1471-2407-14-244
  • Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, Zhu MH, Zhang SH. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res 2011; 17:710-20; PMID:21196414; http://dx.doi.org/10.1158/1078-0432.CCR-10-0331
  • Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012; 208:541-8; PMID:22824148; http://dx.doi.org/10.1016/j.prp.2012.06.001
  • Zhao G, Wang B, Liu Y, Zhang JG, Deng SC, Qin Q, Tian K, Li X, Zhu S, Niu Y, et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 2013; 12:2569-80; PMID:24013097; http://dx.doi.org/10.1158/1535-7163.MCT-13-0296
  • Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2002; 2:9-15; PMID:12150820; http://dx.doi.org/10.1016/S1535-6108(02)00091-0
  • Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13:83-96; PMID:23303139; http://dx.doi.org/10.1038/nrc3430
  • Huang M, Zhang H, Liu T, Tian D, Gu L, Zhou M. Triptolide inhibits MDM2 and induces apoptosis in acute lymphoblastic leukemia cells through a p53-independent pathway. Mol Cancer Ther 2013; 12:184-94; PMID:23243057; http://dx.doi.org/10.1158/1535-7163.MCT-12-0425
  • Jung CH, Kim J, Park JK, Hwang SG, Moon SK, Kim WJ, Um HD. Mdm2 increases cellular invasiveness by binding to and stabilizing the Slug mRNA. Cancer Lett 2013; 335:270-7; PMID:23438693; http://dx.doi.org/10.1016/j.canlet.2013.02.035
  • Kaindl U, Morak M, Portsmouth C, Mecklenbrauker A, Kauer M, Zeginigg M, Attarbaschi A, Haas OA, Panzer-Grümayer R. Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia. Leukemia 2014; 28:600-8; PMID:24240203; http://dx.doi.org/10.1038/leu.2013.345
  • Carvajal D, Tovar C, Yang H, Vu BT, Heimbrook DC, Vassilev LT. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res 2005; 65:1918-24; PMID:15753391; http://dx.doi.org/10.1158/0008-5472.CAN-04-3576
  • Chaar I, Amara S, Khiari M, Ounissi D, Dhraif M, Ben HAE, Gharbi L, Mzabi S, Bouraoui S. Relationship between MDM2 and p53 alterations in colorectal cancer and their involvement and prognostic value in the Tunisian population. Appl Immunohistochem Mol Morphol 2013; 21:228-36; PMID:22914606
  • Tesz GJ, Guilherme A, Guntur KV, Hubbard AC, Tang X, Chawla A, Czech MP. Tumor necrosis factor alpha (TNFalpha) stimulates Map4k4 expression through TNFalpha receptor 1 signaling to c-Jun and activating transcription factor 2. J Biol Chem 2007; 282:19302-12; PMID:17500068; http://dx.doi.org/10.1074/jbc.M700665200
  • Shimokawa N, Qiu CH, Seki T, Dikic I, Koibuchi N. Phosphorylation of JNK is involved in regulation of H(+)-induced c-Jun expression. Cell Signal 2004; 16:723-9; PMID:15093613; http://dx.doi.org/10.1016/j.cellsig.2003.11.005
  • Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. c-Jun regulates the stability and activity of the p53 homologue, p73. J Biol Chem 2004; 279:44713-22; PMID:15302867; http://dx.doi.org/10.1074/jbc.M407672200
  • Xu YM, Zhu F, Cho YY, Carper A, Peng C, Zheng D, Yao K, Lau AT, Zykova TA, Kim HG, et al. Extracellular signal-regulated kinase 8-mediated c-Jun phosphorylation increases tumorigenesis of human colon cancer. Cancer Res 2010; 70:3218-27; PMID:20395206; http://dx.doi.org/10.1158/0008-5472.CAN-09-4306
  • Chao CH, Chang CC, Wu MJ, Ko HW, Wang D, Hung MC, Yang JY, Chang CJ. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. J Clin Invest 2014; 124:3093-106; PMID:24911147; http://dx.doi.org/10.1172/JCI73351
  • Han TS, Hur K, AUID Oho, Xu G, Choi B, Okugawa Y, Toiyama Y, Oshima H, Oshima M, Lee HJ, et al. MicroRNA-29c mediates initiation of gastric carcinogenesis by directly targeting ITGB1. Gut 2014; 64:203-14; PMID:24870620; http://dx.doi.org/10.1136/gutjnl-2013-306640
  • Liu S, Sun X, Wang M, Hou Y, Zhan Y, Jiang Y, Liu S, Sun X, Wang M, Hou Y, et al. A microRNA 221- and 222-Mediated Feedback Loop, via PDLIM2, Maintains Constitutive Activation of NFkappaB and STAT3 in Colorectal Cancer Cells. Gastroenterology 2014; 147:847-859; PMID:24931456; http://dx.doi.org/10.1053/j.gastro.2014.06.006
  • Tan YG, Zhang YF, Guo CJ, Yang M, Chen MY. Screening of differentially expressed microRNA in ulcerative colitis related colorectal cancer. Asian Pac J Trop Med 2013; 6:972-6; PMID:24144030; http://dx.doi.org/10.1016/S1995-7645(13)60174-1
  • Meng Z, Fu X, Chen X, Zeng S, Tian Y, Jove R, Xu R, Huang W. miR-194 is a marker of hepatic epithelial cells and suppresses metastasis of liver cancer cells in mice. Hepatology 2010; 52:2148-57; PMID:20979124; http://dx.doi.org/10.1002/hep.23915
  • Selth LA, Townley SL, Bert AG, Stricker PD, Sutherland PD, Horvath LG, Goodall GJ, Butler LM, Tilley WD. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 2013; 109:641-50; PMID:23846169; http://dx.doi.org/10.1038/bjc.2013.369
  • Wright JH, Wang X, Manning G, LaMere BJ, Le P, Zhu S, Khatry D, Flanagan PM, Buckley SD, Whyte DB, et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003; 23:2068-82; PMID:12612079; http://dx.doi.org/10.1128/MCB.23.6.2068-2082.2003
  • Qiu MH, Qian YM, Zhao XL, Wang SM, Feng XJ, Chen XF, Zhang SH. Expression and prognostic significance of MAP4K4 in lung adenocarcinoma. Pathol Res Pract 2012; 208:541-8; PMID:22824148; http://dx.doi.org/10.1016/j.prp.2012.06.001
  • Ye Y, Li X, Yang J, Miao S, Wang S, Chen Y, Xia X, Wu X, Zhang J, Zhou Y, et al. MDM2 is a useful prognostic biomarker for resectable gastric cancer. Cancer Sci 2013; 104:590-8; PMID:23347235; http://dx.doi.org/10.1111/cas.12111
  • Yu Q, Li Y, Mu K, Li Z, Meng Q, Wu X, Wang Y, Li L. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations. Diagn Pathol 2014; 9:71; PMID:24667108; http://dx.doi.org/10.1186/1746-1596-9-71
  • Watanabe T, Takeda A, Mise K, Okuno T, Suzuki T, Minami N, Imai H. Stage-specific expression of microRNAs during Xenopus development. FEBS Lett 2005; 579:318-24; PMID:15642338; http://dx.doi.org/10.1016/j.febslet.2004.11.067
  • Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression. Nat Methods 2004; 1:47-53; PMID:15782152; http://dx.doi.org/10.1038/nmeth704
  • Collins CS, Hong J, Sapinoso L, Zhou Y, Liu Z, Micklash K, Schultz PG, Hampton GM. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006; 103:3775-80; PMID:16537454; http://dx.doi.org/10.1073/pnas.0600040103
  • Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, et al. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One 2010; 5:e10630; PMID:20498843; http://dx.doi.org/10.1371/journal.pone.0010630
  • Lee BL, Lee HS, Jung J, Cho SJ, Chung HY, Kim WH, Jin YW, Kim CS, Nam SY. Nuclear factor-κB activation correlates with better prognosis and Akt activation in human gastric cancer. Clinical cancer research 2005; 11:2518-25; PMID:15814628; http://dx.doi.org/10.1158/1078-0432.CCR-04-1282
  • Li L, Wang L, Song P, Geng X, Liang X, Zhou M, Wang Y, Chen C, Jia J, Zeng J. Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis. Mol Cancer 2014; 13:81; PMID:24716659; http://dx.doi.org/10.1186/1476-4598-13-81

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.